EGFR and non-small cell lung carcinoma: Another randomized, multicentric, phase 2 trial, the EMERGING-CTONG 1103, compared neoadjuvant chemotherapy with erlotinib in patients with stage IIIA N2 EGFR-mutant NSCLC.